Clinical trial
Hypofractionated Radiotherapy Combined With Toripalimab and Chemotherapy +/- Target Therapy for Locally Recurrent Rectal Cancer: a Single-arm, Two-cohort, Phase II Trial (TORCH-R)
NCT05628038 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Hypofractionated Radiotherapy Combined With Toripalimab and Chemotherapy +/- Target Therapy for Locally Recurrent Rectal Cancer: a Single-arm, Two-cohort, Phase II Trial (TORCH-R)
- Lead sponsor
- Fudan University
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- November 30, 2022
- Completion date
- December 1, 2025
- Enrollment
- 93 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent rectal cancer